Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise amounts of NO to the lungs for the treatment of respiratory and other diseases.
“Our goal is to eliminate the use of cylinder-based NO systems currently used in hospitals around the world and potentially enter the home market to treat certain respiratory conditions,” Steve Lisi, chairman and CEO, says in an interview with BioTuesdays.
Beyond Air hopes to file for premarket approval with the FDA around the end of September 2019 for its cylinder-free NO generator and delivery system, the LungFit, to treat pulmonary hypertension (PH), or a narrowing of the pulmonary arteries in certain ventilated patients.
In January 2019, Beyond Air licensed commercial rights to LungFit PH to Circassia Pharmaceuticals (LSE:CIR) of London, a specialty pharmaceutical company focused on respiratory diseases, for the U.S. and China markets. Circassia plans a U.S. commercial launch in the second quarter of 2020.
|
|
